IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association
Wang, Ji-Guang1; Kario, Kazuomi2; Lau, Titus3; Wei, Yong Quek4; Park, Chang Gyu5; Kim, Cheol Ho6; Huang, Jun7; Zhang, Weizhong1; Li, Yong8; Yan, Peter9,10; Hu, Dayi11
关键词ambulatory blood pressure calcium channel blockers cardiovascular endpoints randomized controlled trials target organ damage
刊名HYPERTENSION RESEARCH
2011-04-01
DOI10.1038/hr.2010.259
34期:4页:423-430
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Peripheral Vascular Disease
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]CONVERTING ENZYME-INHIBITOR ; ISOLATED SYSTOLIC HYPERTENSION ; ANGIOTENSIN RECEPTOR BLOCKERS ; AMBULATORY BLOOD-PRESSURE ; LIPID-LOWERING TREATMENT ; MYOCARDIAL-INFARCTION ; RANDOMIZED-TRIAL ; CARDIOVASCULAR EVENTS ; NIFEDIPINE-RETARD ; CHINESE PATIENTS
英文摘要

Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association′s Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease. Hypertension Research (2011) 34, 423-430; doi:10.1038/hr.2010.259; published online 13 January 2011

语种英语
WOS记录号WOS:000289194100003
项目编号30871360 ; 30871081 ; 2006BAI01A03 ; 07JC14047 ; 06QA14043 ; 07ZZ32 ; 08SG20 ; SHDC12007318 ; IC15-CT98-0329-EPOGH ; LSHM-CT-2006-037093 ; HEALTH-F4-2007-201550
资助机构Pfizer, China ; National Natural Science Foundation of China ; Ministry of Science and Technology, Beijing, China ; Shanghai Commissions of Science and Technology and Education ; Shanghai Shenkang Hospital Development Centre ; European Union ; AstraZeneca ; Bayer ; GSK ; Merck ; Novartis ; Pfizer ; Sankyo ; Servier
引用统计
被引频次:33[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66517
专题北京大学第二临床医学院_心血管内科
作者单位1.Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hypertens, Ctr Epidemiol Studies & Clin Trials,Ruijin Hosp, Shanghai 200025, Peoples R China
2.Jichi Med Univ, Sch Med, Dept Cardiovasc Med, Tochigi, Japan
3.Natl Univ Singapore Hosp, Dept Med, Singapore, Singapore
4.Tan Tock Seng Hosp, Dept Cardiol, Singapore, Singapore
5.Gleneagles Hosp, Singapore, Singapore
6.Mt Elizabeth Hosp, Singapore, Singapore
7.Korea Univ, Sch Med, Guro Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea
8.Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Songnam, South Korea
9.Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Peoples R China
10.Fudan Univ, Shanghai Med Coll, Hushan Hosp, Dept Cardiol, Shanghai 200433, Peoples R China
11.Beijing Univ, Renmin Hosp, Dept Cardiol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Wang, Ji-Guang,Kario, Kazuomi,Lau, Titus,et al. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association[J]. HYPERTENSION RESEARCH,2011,34(4):423-430.
APA Wang, Ji-Guang.,Kario, Kazuomi.,Lau, Titus.,Wei, Yong Quek.,Park, Chang Gyu.,...&Hu, Dayi.(2011).Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association.HYPERTENSION RESEARCH,34(4),423-430.
MLA Wang, Ji-Guang,et al."Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association".HYPERTENSION RESEARCH 34.4(2011):423-430.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Ji-Guang]的文章
[Kario, Kazuomi]的文章
[Lau, Titus]的文章
百度学术
百度学术中相似的文章
[Wang, Ji-Guang]的文章
[Kario, Kazuomi]的文章
[Lau, Titus]的文章
必应学术
必应学术中相似的文章
[Wang, Ji-Guang]的文章
[Kario, Kazuomi]的文章
[Lau, Titus]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。